Drug

Fluorodeoxyglucose F18

In clinical development

Emerging researchLate-stage developmentCooling momentum

Also known as (18F)-FDG, 18-F FDG, 18F-FDG, 18F-Fluorodeoxyglucose+7 more

(18F)-FDG, 18-F FDG, 18F-FDG, 18F-Fluorodeoxyglucose, Fludeoxyglucose (18F), Fluorine (18F) fludeoxyglucose, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18, Fludeoxyglucose F18, Fludeoxyglucose, F-18.

RxNorm1362737 ChEMBLCHEMBL1808698UNII0Z5B2CJX4D

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Open, Non-inferiority Phase III Clinical Study to Evaluate the Efficacy of 18F-Alfatide Injection PET/CT Compared With 18F-FDG PET/CT in the Diagnosis of Lymph Node Metastasis in Non-small Cell Lung Cancer

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Clinical trial2026-07-10Results expected Q4 2029 · ClinicalTrials.gov

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Clinical trial2026-07-09Results expected Q1 2027 · ClinicalTrials.gov

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Clinical trial2026-07-09Results expected Q2 2031 · ClinicalTrials.gov

NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab

Clinical trial2026-07-09Results expected Q4 2026 · ClinicalTrials.gov

Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma

Clinical trial2026-07-09Results expected Q4 2029 · ClinicalTrials.gov

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

Clinical trial2026-07-09Results expected Q3 2027 · ClinicalTrials.gov

An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders.

Research2025-06-27Neurology

Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.

Research2024-04-01Journal of nuclear medicine : official publication, Society of Nuclear Medicine

68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer.

Research2024-01-04The Journal of clinical investigation

2023 ESC Guidelines for the management of endocarditis.

Research2023-10-01European heart journal

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Fluorodeoxyglucose F18

Aliases & brands

(18F)-FDG18-F FDG18F-FDG18F-FluorodeoxyglucoseFludeoxyglucose (18F)Fluorine (18F) fludeoxyglucoseFluorine-18 2-Fluoro-2-deoxy-D-GlucoseFLUDEOXYGLUCOSE F 18FLUDEOXYGLUCOSE F-18Fludeoxyglucose F18Fludeoxyglucose, F-18

RxNorm CUI

1362737

ChEMBL ID

CHEMBL1808698

UNII

0Z5B2CJX4D

Clinical trials

147 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

147

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 147

Early Phase 119Phase 126Phase 1 / 29Phase 249Phase 2 / 33Phase 37Phase 44Phase N / A30

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

CHORD1 - CHOlesterol Lowering and Residual Risk in Diabetes, Type 1

RecruitingPH IVNYU Langone Healthn=1252027

Ultra-long Field-Of-View Positron Emission Tomography for Characterization of Indeterminate Lung Nodules: a Pilot Study Exploring Opportunities for Clinical Research

RecruitingPH IVUniversity Medical Center Groningenn=202025

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

CompletedPH IVMayo Clinicn=802023

Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-Week, Placebo-Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computer Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation in Patients With Eosinophilic Asthma

TerminatedPH IVTeva Branded Pharmaceutical Products R&D, Inc.n=52017

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma

RecruitingPH IIIAlliance for Clinical Trials in Oncologyn=4212038

Recent completions

Trials that read out recently, adding to the completed evidence base.

Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

CompletedN/AUnion Hospital, Tongji Medical College, Huazhong University of Science and Technologyn=272026

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

CompletedPH IINational Cancer Institute (NCI)n=1352025

Ideal Imaging Time Point Assessment for Spinal Cord Lesions of Unknown Etiology With FDG PET-MRI

CompletedN/AM.D. Anderson Cancer Centern=112024

Creating Metabolic Vulnerabilities in Patients with EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR with Osimertinib

CompletedPH IIJonsson Comprehensive Cancer Centern=122024

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

CompletedPH IVMayo Clinicn=802023

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)

CompletedPH IISWOG Cancer Research Networkn=1592023

Research activity

18 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

19972025

Most influential

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009 · 2,644 cites

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

European journal of nuclear medicine and molecular imaging · 2015 · 2,182 cites

Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

Annals of neurology · 1997 · 1,196 cites

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2007 · 1,031 cites

2023 ESC Guidelines for the management of endocarditis.

European heart journal · 2023 · 1,026 cites

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Brain : a journal of neurology · 2016 · 955 cites

Related diseases

8 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Alzheimer's Disease5 Endocarditis, Bacterial3 Neoplasms3 Breast Neoplasms2 Endocarditis2 Head and Neck Neoplasms2 Lung Neoplasms2 Prosthesis-Related Infections2

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Ipilimumab

Studied across 6 of the same disease areas as Fluorodeoxyglucose F18 in the shared literature.

6 shared diseases1 shared paper

Imatinib Mesylate

Studied across 4 of the same disease areas as Fluorodeoxyglucose F18 in the shared literature.

4 shared diseases1 shared paper

Deoxyglucose

Studied across the same disease area as Fluorodeoxyglucose F18 in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials